Individuals living with type 2 diabetes (T2DM) and high cardiovascular (CV) risk are more susceptible to chronic kidney disease (CKD) and kidney failure. With approximately 20–50% of adults with T2DM ultimately developing CKD, an important goal of therapy is to reduce or prevent the progression of this complication.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) approved for treatment of T2DM. In proof-of-concept and Phase 2 studies, tirzepatide improved beta cell function and insulin sensitivity when compared with certain GLP-1 RAs. Extending these observations, the therapeutic efficacy, safety and tolerability of tirzepatide versus placebo and other glucose-lowering drugs were evaluated in the SURPASS clinical trial programme.



Sign up for a free ASCEND account to continue reading.

ASCEND provides CME-accredited content designed to improve the care of people living with diabetes and obesity worldwide. Watch experts share their clinical insights, talk through case studies, address frequently asked questions, and much more!

Already a member? Login